Meningiomas and Proteomics: Focus on New Potential Biomarkers and Molecular Pathways

Overview

Journal Cancer Genomics Proteomics

Specialties Biochemistry
Genetics
Oncology

Date 2016 Aug 28

PMID 27566655

Citations 18

Authors

Rosaria Viola Abbritti

Francesca Polito

Maria Cucinotta

Claudio Lo Giudice

Maria Caffo

Chiara Tomasello

Antonino Germano

Mohammed Aguennouz

Affiliations

Soon will be listed here.

Abstract

Meningiomas are one of the most common tumors affecting the central nervous system, exhibiting a great heterogeneity in grading, treatment and molecular background. This article provides an overview of the current literature regarding the molecular aspect of meningiomas. Analysis of potential biomarkers in serum, cerebrospinal fluid (CSF) and pathological tissues was reported. Applying bioinformatic methods and matching the common proteic profile, arising from different biological samples, we highlighted the role of nine proteins, particularly related to tumorigenesis and grading of meningiomas: serpin peptidase inhibitor alpha 1, ceruloplasmin, hemopexin, albumin, C3, apolipoprotein, haptoglobin, amyloid-P-component serum and alpha-1-beta-glycoprotein. These proteins and their associated pathways, including complement and coagulation cascades, plasma lipoprotein particle remodeling and lipid metabolism could be considered possible diagnostic, prognostic biomarkers, and eventually therapeutic targets. Further investigations are needed to better characterize the role of these proteins and pathways in meningiomas. The role of new therapeutic strategies are also discussed.

Citing Articles

Advances in Mass Spectrometry of Gangliosides Expressed in Brain Cancers.

Biricioiu M, Sarbu M, Ica R, Vukelic Z, Kalanj-Bognar S, Zamfir A Int J Mol Sci. 2024; 25(2).

PMID: 38279335 PMC: 10816113. DOI: 10.3390/ijms25021335.

Unveiling a Biomarker Signature of Meningioma: The Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis.

Halabi R, Dakroub F, Haider M, Patel S, Amhaz N, Reslan M Cancers (Basel). 2023; 15(22).

PMID: 38001599 PMC: 10670806. DOI: 10.3390/cancers15225339.

Decoding meningioma heterogeneity and neoplastic cell-macrophage interaction through single-cell transcriptome profiling across pathological grades.

Fan H, Song L, Fan J, Ma J, Li X, Zhang J J Transl Med. 2023; 21(1):751.

PMID: 37880655 PMC: 10599053. DOI: 10.1186/s12967-023-04445-4.

Proteomic interrogation of the meninges reveals the molecular identities of structural components and regional distinctions along the CNS axis.

Santorella E, Balsbaugh J, Ge S, Saboori P, Baker D, Pachter J Fluids Barriers CNS. 2023; 20(1):74.

PMID: 37858244 PMC: 10588166. DOI: 10.1186/s12987-023-00473-w.

A large-scale targeted proteomics of serum and tissue shows the utility of classifying high grade and low grade meningioma tumors.

Halder A, Biswas D, Chauhan A, Saha A, Auromahima S, Yadav D Clin Proteomics. 2023; 20(1):41.

PMID: 37770851 PMC: 10540342. DOI: 10.1186/s12014-023-09426-9.

References

Nunes F, Shen Y, Niida Y, Beauchamp R, Stemmer-Rachamimov A, Ramesh V . Inactivation patterns of NF2 and DAL-1/4.1B (EPB41L3) in sporadic meningioma. Cancer Genet Cytogenet. 2005; 162(2):135-9. DOI: 10.1016/j.cancergencyto.2005.04.003. View

Kleihues P, Louis D, Scheithauer B, Rorke L, Reifenberger G, Burger P . The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002; 61(3):215-25; discussion 226-9. DOI: 10.1093/jnen/61.3.215. View

Saydam O, Senol O, Schaaij-Visser T, Pham T, Piersma S, Stemmer-Rachamimov A . Comparative protein profiling reveals minichromosome maintenance (MCM) proteins as novel potential tumor markers for meningiomas. J Proteome Res. 2009; 9(1):485-94. PMC: 2810358. DOI: 10.1021/pr900834h. View

Paek S, Kim D, Park C, Phi J, Kim Y, Im S . The role of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinase in microcystic meningiomas. Oncol Rep. 2006; 16(1):49-56. View

Okamoto H, Li J, Vortmeyer A, Jaffe H, Lee Y, Glasker S . Comparative proteomic profiles of meningioma subtypes. Cancer Res. 2006; 66(20):10199-204. DOI: 10.1158/0008-5472.CAN-06-0955. View

Kreuter J, Hekmatara T, Dreis S, Vogel T, Gelperina S, Langer K . Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J Control Release. 2007; 118(1):54-8. DOI: 10.1016/j.jconrel.2006.12.012. View

Bouwens T, Trouw L, Veerhuis R, Dirven C, Lamfers M, Al-Khawaja H . Complement activation in Glioblastoma multiforme pathophysiology: evidence from serum levels and presence of complement activation products in tumor tissue. J Neuroimmunol. 2014; 278:271-6. DOI: 10.1016/j.jneuroim.2014.11.016. View

Sharma S, Ray S, Mukherjee S, Moiyadi A, Sridhar E, Srivastava S . Multipronged quantitative proteomic analyses indicate modulation of various signal transduction pathways in human meningiomas. Proteomics. 2014; 15(2-3):394-407. DOI: 10.1002/pmic.201400328. View

Zhao M, Li Z, Qu H . An evidence-based knowledgebase of metastasis suppressors to identify key pathways relevant to cancer metastasis. Sci Rep. 2015; 5:15478. PMC: 4614344. DOI: 10.1038/srep15478. View

10.

Laurendeau I, Ferrer M, Garrido D, DHaene N, Ciavarelli P, Basso A . Gene expression profiling of the hedgehog signaling pathway in human meningiomas. Mol Med. 2010; 16(7-8):262-70. PMC: 2896461. DOI: 10.2119/molmed.2010.00005. View

11.

Bello M, Aminoso C, Lopez-Marin I, Arjona D, Gonzalez-Gomez P, Alonso M . DNA methylation of multiple promoter-associated CpG islands in meningiomas: relationship with the allelic status at 1p and 22q. Acta Neuropathol. 2004; 108(5):413-21. DOI: 10.1007/s00401-004-0911-6. View

12.

McCarthy R, Kosman D . Activation of C6 glioblastoma cell ceruloplasmin expression by neighboring human brain endothelia-derived interleukins in an in vitro blood-brain barrier model system. Cell Commun Signal. 2014; 12:65. PMC: 4200123. DOI: 10.1186/s12964-014-0065-7. View

13.

Hashemi M, Pooladi M, Razi Abad S . The investigation of changes in proteins expression (Apolipoprotein A1 and albumin) in malignant astrocytoma brain tumor. J Cancer Res Ther. 2014; 10(1):107-11. DOI: 10.4103/0973-1482.131413. View

14.

Jun P, Hong C, Lal A, Wong J, McDermott M, Bollen A . Epigenetic silencing of the kinase tumor suppressor WNK2 is tumor-type and tumor-grade specific. Neuro Oncol. 2008; 11(4):414-22. PMC: 2743221. DOI: 10.1215/15228517-2008-096. View

15.

Higashiyama M, Doi O, Kodama K, Yokouchi H, Tateishi R . An evaluation of the prognostic significance of alpha-1-antitrypsin expression in adenocarcinomas of the lung: an immunohistochemical analysis. Br J Cancer. 1992; 65(2):300-2. PMC: 1977730. DOI: 10.1038/bjc.1992.60. View

16.

Rutkowski M, Sughrue M, Kane A, Mills S, Parsa A . Cancer and the complement cascade. Mol Cancer Res. 2010; 8(11):1453-65. DOI: 10.1158/1541-7786.MCR-10-0225. View

17.

Boccaccio C, Medico E . Cancer and blood coagulation. Cell Mol Life Sci. 2006; 63(9):1024-7. PMC: 11135989. DOI: 10.1007/s00018-005-5570-9. View

18.

Martinez-Glez V, Alvarez L, Franco-Hernandez C, Torres-Martin M, de Campos J, Isla A . Genomic deletions at 1p and 14q are associated with an abnormal cDNA microarray gene expression pattern in meningiomas but not in schwannomas. Cancer Genet Cytogenet. 2009; 196(1):1-6. DOI: 10.1016/j.cancergencyto.2009.08.003. View

19.

Davis F, Kupelian V, Freels S, McCarthy B, Surawicz T . Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro Oncol. 2001; 3(3):152-8. PMC: 1920611. DOI: 10.1093/neuonc/3.3.152. View

20.

Tsai B, Hoverter N, Waterman M . Blending hippo and WNT: sharing messengers and regulation. Cell. 2012; 151(7):1401-3. DOI: 10.1016/j.cell.2012.12.007. View